Duke Health joined the Durham community to celebrate Pride: Durham, NC 2026. Duke showed its support at the event’s Pride Vendor & Food Truck Rodeo held at Durham Central Park on September 27.

Culture shapes how people move through the world, what they value, and often, the career paths they pursue.

Duke surgical oncologist Jennifer Plichta, MD, MS, is pushing the evolution of personalized care — combining data, research, and a deeply patient-centered approach to help patients navigate an increasingly complex landscape of breast cancer risk, prevention, and treatment.

Mary Klotman, MD, has decided to step down as dean of the Duke University School of Medicine and as executive vice president for health affairs at Duke University and chief academic officer f

Artificial intelligence is creating new opportunities to advance discovery, education, patient care, and the way we work. In this conversation, Dr. Mary E. Klotman, sits down with Dr. Christopher Lindsell, vice dean for data science and AI for the Duke University School of Medicine, to discuss Duke's vision for AI and data science.

Elizabeth Ramirez-Washka, JD, associate general counsel for Duke University and Duke University Health System, credits her grandparents with teaching her to work hard, value education, and pay it forward. Those lessons have guided her from advocating for her family while growing up in Texas to creating opportunities for others at Duke and beyond.

New research from Duke University School of Medicine points to a surprising possibility: a naturally occurring human gut bacterium produces a sugar molecule that helps obese mice increase energy expenditure and reduce visceral fat that accumulates around internal organs and is associated with diabetes and heart disease.

A discovery that began in a Duke laboratory is now being tested in Duke patients, offering a potential new approach to diagnosing cardiac sarcoidosis, which can be life-threatening and difficult to diagnose.

Duke researchers are leading a phase I clinical trial to evaluate a new experimental treatment for glioblastoma, one of the most aggressive and deadly forms of brain cancer. The drug is a type of immunotherapy known as a Brain Bispecific T-cell Engager (BRiTE), which is designed to cross the blood-brain barrier and to help the patient’s own immune cells (T-cells) recognize and attack cancer cells. 

A team led by Duke neonatologist Noelle Younge, MD, MHS, has found evidence that the intestinal microbiome plays a direct role in slow weight gain and poor growth in preterm infants.